General Information

We are a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using our nitric oxide platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. Our lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne.


Employees: 63
Founded: 2006
Contact Information
Address 4222 Emperor Boulevard, Suite 200 Durham, North Carolina 27703, USA
Phone Number (919) 485-8080
Web Address
View Prospectus: Novan
Financial Information
Market Cap $168.5mil
Revenues $0 mil (last 12 months)
Net Income $-46.4 mil (last 12 months)
IPO Profile
Symbol NOVN
Exchange NASDAQ
Shares (millions): 4.1
Price range $11.00 - $11.00
Est. $ Volume $45.1 mil
Manager / Joint Managers Piper Jaffray
CO-Managers JMP Securities/ Wedbush PacGrow
Expected To Trade: 9/21/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change